|
The Breast Cancer Initiative: Addressing Chemotherapy Resistance
A CME/CE Web-Based Activity
Prior to participating in this activity, please review the information on this page. Estimated time to complete each module: 60 minutes
PROGRAM OVERVIEW Guidelines and strategies for treating patients with metastatic breast cancer (mBC) are continually changing due to advancements in clinical knowledge and ongoing research. At present, the most active drugs are the anthracyclines and the taxanes. However, responses are often short-lived, and disease progression is almost inevitable. Tumor resistance to cytotoxic agents is commonly observed and occurs through various mechanisms, including biological resistance at the cellular level (eg, altered membrane transport involving product of the multidrug resistance [MDR] gene). Most recently, epothilones have entered the clinical arena for treating taxane- and anthracycline-refractory metastatic disease. This new class of agents differs from taxanes in their interaction with microtubules and mechanisms of cellular resistance. In this CME/CE activity, The Breast Cancer Initiative: Addressing Chemotherapy Resistance, each of the 3 modules will familiarize participants with current efficacy and safety data for emerging therapies that overcome resistance, and will help define the optimal position for these therapies within the spectrum of treatment options.
TARGET AUDIENCE The target audience for this activity includes medical and practicing oncologists, oncology nurses, and nurse practitioners who work with patients with metastatic breast cancer.
LEARNING OBJECTIVES Module 1: Mechanisms for Overcoming Anthracycline and Taxane Resistance
Module 2: After Anthracyclines and Taxanes: Emerging Agents and Clinical Data
Module3: Overcoming Anthracycline and Taxane Resistance: Managing Toxicities
METHOD
OF PARTICIPATION
This activity is provided free of charge to participants.
ACCREDITATION/DESIGNATION OF CREDIT STATEMENT Veritas Institute for Medical Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.
Physicians: Veritas Institute for Medical Education, Inc. designates each educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses: Veritas Institute for Medical Education, Inc. approved by the California Board of Registered Nursing, Provider #13986, for 1 Contact Hour. Nurse Practitioners: Veritas Institute for Medical Education, Inc. approved as a provider for nurse practitioner continuing education by the American Academy of Nurse Practitioners: AANP Provider number 040309. Each program has been approved for 1.0 contact hour(s) of continuing education (which includes 1.0 hour(s) of pharmacology). FINANCIAL DISCLOSURE In accordance with the ACCME’s Standards for Commercial Support, all CME/CE providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME/CE content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME/CE activity content over which the individual has control. Disclosures are as follows: Sandra M. Swain, MD: Genentech, Inc. (consultant), Roche Pharmaceuticals, sanofi-aventis (speakers bureau) Una Hopkins, NP: Bristol-Myers Squibb Company, Genentech, Inc. (consultant), Genomic Health, Inc., MGI PHARMA, INC., Pfizer Inc (speakers bureau), sanofi-aventis (speakers bureau, consultant) Linda T. Vahdat, MD: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc., Pfizer Inc (grant/research support) The independent content reviewer, Electa Stern, PharmD: Ortho McNeil, Astelas, sanofi-aventis (advisory board) The staff of Veritas Institute for Medical Education, Inc. has nothing to disclose.
OFF-LABEL/INVESTIGATIONAL USES OF DRUGS/MEDICAL DEVICES DISCLOSURE Participants are advised that this CME/CE activity will contain references to unlabeled/unapproved/investigational uses of drugs to treat patients with breast cancer.
DISCLAIMER The opinions expressed in this activity are those of the presenters and do not necessarily reflect those of Veritas Institute for Medical Education, Inc., or Bristol-Myers Squibb Company. Please consult the appropriate package insert for full prescribing information on all drug therapies discussed.
Copyright © 2008 Veritas Institute for Medical Education, Inc. All rights reserved. Terms and Conditions/Privacy Policy
|
|||||||||||||||||
